ArticleBMC pregnancy and childbirth2025
Retrospective analysis of adverse pregnancy outcomes associated with hepatitis B virus infection.
Article in BMC pregnancy and childbirth, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- The impact of maternal chronic viral hepatitis infections on pregnancy and neonatal outcomes in in vitro fertilization: a systematic review and meta-analysis.Journal of ovarian research · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundHepatitis B virus (HBV) infection poses significant risks during pregnancy, potentially leading to adverse outcomes. This study evaluates the risk factors and associated biochemical parameters contributing to poor pregnancy outcomes in HBV-infected pregnant women.
methodsWe conducted a retrospective case-control study encompassing 472 pregnant women with HBV infections treated at our hospital between May 2021 and May 2024. Participants were divided into two groups: those with adverse pregnancy outcomes (n = 158) and those with favorable outcomes (n = 314). Adverse outcomes included conditions such as Gestational Diabetes Mellitus (GDM), Hypertensive Disorders of Pregnancy (HDP), Intrahepatic Cholestasis of Pregnancy (ICP), Preterm Birth (PTB), Fetal Distress (FD), Postpartum Hemorrhage (PPH), Postpartum Anemia (PPA), Low Birth Weight (LBW), Macrosomia, Birth Defects, and Stillbirth. We analyzed liver function and coagulation indices, performed receiver operating characteristic (ROC) curve analysis to identify predictive thresholds, conducted subgroup analysis stratified by HBeAg status, and performed statistical analyses using SPSS and R software.
resultsSignificant determinants of adverse pregnancy outcomes include advanced maternal age (OR = 1.114, 95% CI = 1.038–1.196, P = 0.003) and Hepatitis B e Antigen (HBeAg) positivity (OR = 7.506, 95% CI = 4.459–12.636, P < 0.001). Impaired liver function, indicated by elevated AST (OR = 1.016, 95% CI = 1.001–1.030, P = 0.034) and ALT (OR = 1.046, 95% CI = 1.023–1.070, P < 0.001), was more prevalent in the poor outcome group. Coagulation abnormalities such as prolonged PT (OR = 1.298, 95% CI = 1.069–1.577, P = 0.009) and elevated D-Dimer (OR = 5.079, 95% CI = 1.590-16.228, P = 0.006) were associated with adverse outcomes. Antiviral drug treatment was protective against poor outcomes (OR = 0.491, 95% CI = 0.292–0.828, P = 0.008). ROC analysis identified predictive thresholds for adverse outcomes. Subgroup analysis confirmed HBeAg-positive women exhibited significantly worse liver function, coagulation profiles, and higher rates of specific adverse outcomes (GDM, ICP, PTB, PPA) (P < 0.05).
conclusionAdvanced maternal age, HBeAg positivity, impaired liver function, and coagulation abnormalities are significant risk factors for adverse pregnancy outcomes in HBV-infected women. Antiviral treatment mitigates these risks. ROC-derived thresholds and HBeAg status provide valuable insights for risk stratification. These findings underscore the importance of comprehensive monitoring and management strategies, particularly for HBeAg-positive women, to improve pregnancy outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.